Dyne Therapeutics (DYN) Faces Market Pressure After Novartis DM1

Dyne Therapeutics (DYN) shares dropped 10% after-hours on plans to raise $300M via a stock offering. This follows FDA acceptance of its z-rostudirsen application for Duchenne muscular dystrophy, with a decision expected by January 2027. The company aims to use proceeds for clinical development and commercial infrastructure. DYN stock is up 22% year-to-date.

Novartis (NVS) shares fell 14% after a late-stage trial for del-desiran in myotonic dystrophy type 1 failed its primary test, marking its second trial failure in a week. The drug showed activity on secondary measures, and the company will review data. Dyne Therapeutics (DYN) and Sarepta Therapeutics (SRPT) also declined in sympathy.

Dyne Therapeutics (DYN) stock fell 23% to $18.60 on Tuesday, despite plans to present one-year clinical data from its Phase 1/2 ACHIEVE trial for myotonic dystrophy type 1. The company will share six- and 12-month data from the trial and updated safety data at upcoming medical meetings. Dyne's 52-week range is $11.92 to $27.31.

Dyne Therapeutics (DYN) shares fell 28% after Novartis' Phase III trial for a similar drug failed. Dyne's stock dropped to $17.50, reflecting investor concerns about its pipeline. The company has no revenue, and insiders have sold $168.4M in shares over 12 months. Dyne's GF Score is 34/100, indicating financial and operational challenges.

Dyne Therapeutics (DYN) shares fell after Novartis' DM1 trial failure raised concerns about Dyne's pipeline. DYN has no revenue, a $4.53B market cap, and a GF Score of 34. Insiders sold $168.4M in shares. Stifel maintains a Buy rating with a $37 target.

Dyne Therapeutics director Jason P. Rhodes sold about $65.2M of DYN common stock on Aug. 13-14, 2026 under a Rule 10b5-1 plan. Prices ranged from $25.00 to $26.20. The sales follow FDA acceptance of Dyne’s zeleciment rostudirsen BLA for Priority Review (target Jan. 21, 2027) and a $375M public offering priced at $20.50.